Terms: = Pancreatic cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
22 results:
1. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
2. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
[TBL] [Abstract] [Full Text] [Related]
3. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
4. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
5. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Rev Esp Patol; 2023; 56(1):32-44. PubMed ID: 36599598
[TBL] [Abstract] [Full Text] [Related]
6. [cancer Therapy Targeting Fusion Gene(fgfr2 Fusion Gene)in Biliary Tract cancer].
Hamaguchi T; Ueno M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1040-1042. PubMed ID: 36281591
[TBL] [Abstract] [Full Text] [Related]
7. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying fgfr2 fusions or rearrangements: A phase II study.
Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
[TBL] [Abstract] [Full Text] [Related]
8. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de-Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Clin Transl Oncol; 2022 Nov; 24(11):2107-2119. PubMed ID: 36008616
[TBL] [Abstract] [Full Text] [Related]
9. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary cancers Treated With Platinum-Based Chemotherapy.
Uson Junior PLS; Majeed U; Yin J; Botrus G; Sonbol MB; Ahn DH; Starr JS; Jones JC; Babiker H; Inabinett SR; Wylie N; Boyle AWR; Bekaii-Saab TS; Gores GJ; Smoot R; Barrett M; Nagalo B; Meurice N; Elliott N; Petit J; Zhou Y; Arora M; Dumbauld C; Barro O; Baker A; Bogenberger J; Buetow K; Mansfield A; Mody K; Borad MJ
JCO Precis Oncol; 2022 Jun; 6(1):e2100274. PubMed ID: 35666960
[TBL] [Abstract] [Full Text] [Related]
10. Deciphering Genetic Alterations of Taiwanese Patients with pancreatic Adenocarcinoma through Targeted Sequencing.
Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
[TBL] [Abstract] [Full Text] [Related]
11. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
12. Stage 4 pancreatic adenocarcinoma harbouring an
Poon D; Tan MH; Khor D
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34511423
[TBL] [Abstract] [Full Text] [Related]
13. Fibroblast growth factor receptor 2 (fgfr2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
[TBL] [Abstract] [Full Text] [Related]
14. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract] [Full Text] [Related]
15. Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease.
Berger AK; Mughal SS; Allgäuer M; Springfeld C; Hackert T; Weber TF; Naumann P; Hutter B; Horak P; Jahn A; Schröck E; Haag GM; Apostolidis L; Jäger D; Stenzinger A; Fröhling S; Glimm H; Heining C
Pancreatology; 2020 Apr; 20(3):425-432. PubMed ID: 32156527
[TBL] [Abstract] [Full Text] [Related]
16. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells.
Ishiwata T
Front Biosci (Landmark Ed); 2018 Jan; 23(4):626-639. PubMed ID: 28930565
[TBL] [Abstract] [Full Text] [Related]
17. cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer.
Ishiwata T
Pathol Int; 2016 Nov; 66(11):601-608. PubMed ID: 27510923
[TBL] [Abstract] [Full Text] [Related]
18. Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Li J; Luo M; Wang Y; Shang B; Dong L
Oncol Rep; 2016 Sep; 36(3):1345-52. PubMed ID: 27430377
[TBL] [Abstract] [Full Text] [Related]
19. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
[TBL] [Abstract] [Full Text] [Related]
20. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.
Zhang H; Hylander BL; LeVea C; Repasky EA; Straubinger RM; Adjei AA; Ma WW
Br J Cancer; 2014 Jan; 110(2):320-9. PubMed ID: 24327018
[TBL] [Abstract] [Full Text] [Related]
[Next]
